Comprehensive Determination of Extractables from Five Different Brands of Stoppers Used for Injectable Products

References

1. 1.↵
   1. Nassar M. N.,
   2. Nesarikar V. V.,
   3. Lozano R.

   Degradation of a lyophilized formulation of BMS-204352: identification of degradants and role of elastomeric closures. Pharm. Dev. Technol. 2005, 10 ( 2) 227– 232.

   OpenUrlPubMed
2. 2.↵
   1. Primeau M.-N.,
   2. Adkinson N. F.,
   3. Hamilton R. G.

   Natural rubber pharmaceutical vial closures release latex allergens that produce skin reactions. J. Allergy Clin. Immunol. 2001, 107 ( 6) 958– 962.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Zhao X.,
   2. Jin S.-H.,
   3. Hu C.-Q.

   The effect of rubber closures on the haze state of ceftriaxone sodium for injection. Drug Dev. Ind. Pharm. 2007, 33 ( 1), 35– 44.

   OpenUrlPubMed
4. 4.↵
   1. Zhang F.,
   2. Chang A.,
   3. Karaisz K.,
   4. Feng R.,
   5. Cai J.

   Structural identification of extractables from rubber closures used for pre-filled semisolid drug applicator by chromatography, mass spectrometry, and organic synthesis. J. Pharm. Biomed. Anal. 2004, 34 ( 5), 841– 849.

   OpenUrlPubMed
5. 5.↵
   1. Jenke D.

   Extractable/leachable substances from plastic materials used as pharmaceutical product containers/devices. J. Pharm. Sci. Technol. 2002, 56 ( 6), 332– 371.

   OpenUrl
6. 6.↵
   1. Bennett C. L.,
   2. Luminari S.,
   3. Nissenson A. R.,
   4. Tallman M. S.,
   5. Klinge S. A.,
   6. McWilliams N.,
   7. McKoy J. M.,
   8. Kim B.,
   9. Lyons A.,
   10. Trifilio S. M.,
   11. Raisch D. W.,
   12. Evens A. M.,
   13. Kuzel T. M.,
   14. Schumock G. T.,
   15. Belknap S. M.,
   16. Locatelli F.,
   17. Rossert J.,
   18. Casadevall N.

   Pure red-cell aplasia and epoetin therapy. N. Eng. J. Med. 2004, 351 ( 14), 1403– 1408.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Zhang X. K.,
   2. Dutky R. C.,
   3. Fales H. M.

   Rubber stoppers as sources of contaminants in electrospray analysis of peptides and proteins. Anal. Chem. 1996, 68 ( 18), 3288– 3289.

   OpenUrlPubMed
8. 8.↵
   FDA Guidance for Industry. Container closure systems for packaging human drugs and biologics, CMC documentation, CDER and CBER, May 1999.
9. 9.↵
   FDA Guidance for Industry. Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products. Chemistry, Manufacturing, and Controls Documentation. http://www.fda.gov/cder/guidance/2180dft.
10. 10.↵
    FDA Guidance for Industry. Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products. Chemistry, Manufacturing, and Controls Documentation. http://www.fda.gov/cder/guidance/4234fnl.
11. 11.↵
    1. Milano C. J.,
    2. Bailey L. C.

    Evaluation of current compendial physiochemical test procedures for pharmaceutical elastomeric closures and development of an improved HPLC procedure. J. Pharm. Sci. Technol. 1999, 53 ( 4), 202– 210.

    OpenUrl
12. 12.↵
    1. DePaolis A.,
    2. Zhu L.,
    3. Gunturi S.,
    4. Deng F.,
    5. Begum S.,
    6. Tolman G.,
    7. Templeman T.,
    8. Ghobrial I.

    Rapid screening of UV absorbing leachables in biologic product placebos. Am. Pharm. Rev. 2006, 9 ( 5), 54, 56– 59.

    OpenUrl
13. 13.↵
    1. Paskiet D. M.

    Strategy for determining extractables from rubber packaging materials in drug products. J. Pharm. Sci. Technol. 1997, 51 ( 6), 248– 251.

    OpenUrl
14. 14.↵
    1. Petersen C.

    New challenges to elastomeric closures. Pharm. Ind. 2002, 64 ( 8A), 899– 907.

    OpenUrl
15. 15.↵
    1. Xiao B.,
    2. Gozo S. K.,
    3. Herz L.

    Development and validation of HPLC methods for the determination of potential extractables from elastomeric stoppers in the presence of a complex surfactant vehicle used in the preparation of parenteral drug products. J. Pharm. Biomed. Anal. 2007, 43 ( 2), 558– 565.

    OpenUrlPubMed
16. 16.↵
    1. Delaunay-Bertoncini N.,
    2. Van der Wielen F. W. M.,
    3. De Voogt P.,
    4. Erlandsson B.,
    5. Schoenmakers P. J.

    Analysis of low-molar-mass materials in commercial rubber samples by Soxhlet and headspace extractions followed by GC-MS analysis. J. Pharm. Biomed. Anal. 2004, 35 ( 5), 1059– 1073.

    OpenUrlPubMed
17. 17.↵
    1. Michulec M.,
    2. Wardencki W.

    The application of single drop extraction technique for chromatographic determination of solvent residues in edible oils and pharmaceutical products. Chromatographia 2006, 64 ( 3–4), 191– 197.

    OpenUrl
18. 18.↵
    1. Perez Pavon J. L.,
    2. del Nogal Sanchez M.,
    3. Garcia Pinto C.,
    4. Fernandez Laespada M. E.,
    5. Moreno Cordero B.

    Use of mass spectrometry methods as a strategy for detection and determination of residual solvents in pharmaceutical products. Anal. Chem. 2006, 78 ( 14), 4901– 4908.

    OpenUrlPubMed
19. 19.↵
    FDA Guidance for Industry. QC3 Impurities: residual solvents, FDA, CDER, CBER, ICH Dec. 1997.
20. 20.↵
    1. Lohmiller J. J.,
    2. Lipman N. S.

    Silicon crystals in water of autoclaved glass bottles. Contemp. Top. Lab. Anim. Sci. 1998, 37 ( 1), 62– 65.

    OpenUrlPubMed
21. 21.↵
    1. Byrne W.

    Reverse Osmosis: A Practical Guide for Industrial Users; Tall Oaks Publishing: Littleton, CO, 1995.
22. 22.↵
    1. Passl W.

    Interactions of parenteral solutions with sulphur-treated glass bottles. J. Pharm. Pharmacol. 1979, 31 ( 11), 721– 725.

    OpenUrlPubMed